350P - Extended adjuvant temozolamide as prognostic factor of longer overall and progression-free survival in glioblastoma multiforme

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Central Nervous System Malignancies
Presenter Sara Póvoa
Citation Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367
Authors S.C. Póvoa1, N. Tavares1, M.J. Ribeiro1, D. Azevedo1, A. Coelho1, A. Fernandes1, A. Costa1, C. Caeiro1, B. Carvalho2, P. Linhares2, L. Osório3, L. Castro4, J. Fonseca5, M. Damasceno1
  • 1Medical Oncology Department, Hospital de S. João, 4200–319 - Porto/PT
  • 2Neurosurgical Department, Hospital de S. João, 4200–319 - Porto/PT
  • 3Radiation Oncology Department, Hospital de S. João, 4200–319 - Porto/PT
  • 4Pathology Department, Hospital de S. João, 4200–319 - Porto/PT
  • 5Neuroradiology Department, Hospital de S. João, 4200–319 - Porto/PT



Glioblastoma multiforme (GBM), the most common malignant primary central nervous system tumour, has significant morbi-mortality. The aim is to determine prognostic factors (PF) of overall survival (OS) and progression-free survival (PFS) in patients treated with Stupp protocol.


Retrospective analysis of GBM patients ≥18 years, diagnosed from March 2004 to December 2014, treated with radiotherapy (RT) plus concomitant and adjuvant temozolomide (aTMZ). OS and PFS were assessed by Kaplan-Meier method and multivariate analysis (MA) was performed using Cox regression.


A total of 213 patients completed concomitant TMZ-RT and were included in final analysis. Majority were males (n = 134), with median age of 61 years old (24-84) and 43.1% ECOG performance status 0. Gross total resection (GTR) was possible in 46.9%, partial resection in 33.3% and stereotactic biopsy (SB) in 19.7%. 197 patients proceeded to aTMZ: 107 suspended


Our results suggest an OS and PFS benefit of extended aTMZ beyond standard 6 cycles, with stronger impact in OS with >12 cycles. The retrospective study design limits conclusions and further validation is necessary in prospective randomized studies.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.